Eleftherios "Lefteris" Michailidis, PhD
Laboratory of Biochemical Pharmacology
Department of Pediatrics
Emory University School of Medicine
Dr. Michailidis joined Emory University in Fall 2021 and has established a multidisciplinary lab focusing on virus-host interactions in HBV and other viruses.
The Michailidis research program focuses on understanding the interaction between viruses and the host using a set of biochemical, cell-based and in vivo methods. In particular, the group is interested in HBV and the development of eradication strategies that involve state-of-the-art primary hepatocyte systems and humanized liver chimeric mice. These systems expand the scope of the research beyond viral hepatitis to other liver-related diseases and fields including fatty liver disease and liver immunometabolism. In addition, they have a strong interest in antiviral mechanisms carried out by interferon-stimulated genes and other host proteins but also small molecule inhibitors in regards to mechanisms of action and resistance. In this direction their main focus has been HIV, HBV, and SARS-CoV-2. To accomplish these goals, they use medium and high-throughput genetic screens (gene overexpression and CRISPR knockout) across different cell systems and in some cases in humanized mice.